

CERTIFICATE OF MAILING


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on February 24, 2004

Sandra Puljic
Sandra Puljic

PATENT

Attorney Docket No. 39739-0028 A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Re Application

Inventor(s): Zhihe Li, et al.

Application No.: 10/626,004

Filed: July 23, 2003

Title Methods For Improvements of Lung Function
Using TGF- β Inhibitors

PATENT APPLICATION

Art Unit: Not Assigned

Examiner: Not Assigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, can be found attached, according to 35 U.S.C. 120, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.


This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☒ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39739-0028 A).

Respectfully submitted,

HELLER EHRMAN WHITE & MCAULIFFE LLP

Dated: February 24, 2004

By: 
Ginger R. Dreger, Reg. No. 33,055

275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7000
Customer No. 25213

INFORMATION DISCLOSURE CITATION PTO-1449		ATTY. DOCKET NO.		SERIAL NO.			
		39739-0028 A		10/626,004			
		APPLICANT Zhihe Li					
		FILING DATE 07/23/2003		GROUP Not Assigned			
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/61576	10/19/2000	PCT	C07D	401/04	<input type="checkbox"/>	<input type="checkbox"/>
	WO 02/40468	05/23/2002	PCT	C07D	401/04		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Dawkins, et al., "Animal models of chronic obstructive pulmonary disease," Thorax, Vol. 56, pp. 972-977, 2001.						
	Derynck, et al., "TGF- β receptor signaling," Biochimica et Biophysica Acta, Vol. 1333, pp. F105-F150, 1997.						
	Hele, "First Siena International Conference on Animal Models of Chronic Obstructive Pulmonary Disease, Certosa di Pontignano, University of Siena, Italy, September 30-October 2, 2001," Respiratory Research, Vol. 3, No. 1, pp. 1-3, 2002.						
	López-Casillas, et al., "Betaglycan Presents Ligand to the TGF β Signaling Receptor," Cell, Vol. 73, pp. 1435-1444, 1993.						
	Massagué, "The Transforming Growth Factor- β Family," Annu. Rev. Cell Biol., Vol. 6, pp. 597-641, 1990.						
	Massagué, "TGF- β Signal Transduction", Annu. Rev. Biochem., Vol. 67, pp. 753-791, 1998.						
	Miyazono, et al, "TGF- β Signaling by Smad Proteins," Advances in Immunology, Vol. 75, pp. 115-157, 2000.						
	Roberts, et al., "The Transforming Growth Factor- β s," Handbook of Experimental Pharmacology, Vol. 95, pp. 419-458, 1990.						
	Whitman, "Smads and early developmental signaling by the TGF β superfamily", Genes & Development, Vol. 12, pp. 2445-2462, 1998.						
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.